Literature DB >> 3994898

An investigation of the cause of accumulation of verapamil during regular dosing in patients.

J B Schwartz, D R Abernethy, A A Taylor, J R Mitchell.   

Abstract

The accumulation of verapamil during regular dosing conditions was studied. Plasma concentrations of verapamil (V) and norverapamil (NV) were measured as were urinary concentrations of verapamil, norverapamil, and four other N- and O-dealkylated metabolites in nine patients after an initial single dose and after chronic oral verapamil administration to steady-state plasma concentrations. Indocyanine green (ICG) clearance was determined immediately prior to the initial verapamil dose and prior to the verapamil washout from regular dosing. An approximately two-fold accumulation of V had occurred during regular dosing. The area under the plasma concentration-time curve (AUC1) after the first dose was 417.4 +/- 276.7 ng ml-1 h (mean +/- s.d.) and increased to 786.5 +/- 54 ng ml-1 h (P less than 0.01) during one dosage interval at steady-state (AUCss). NV also tended to accumulate from an AUC1 of 552.6 +/- 411 to an AUCss 668.7 +/- 332 ng ml-1 h (P less than 0.09). The ratio of AUC-V to AUC-NV was unchanged. The verapamil elimination half-life (t 1/2) increased from 8.4 +/- 4.2 to 12.0 +/- 3.6 h (P less than 0.01) whereas the norverapamil t 1/2 was unchanged. ICG clearance was unchanged. Urinary excretion of NV increased slightly but the ratio of urinary V/NV concentrations was not significantly altered nor was the ratio of four other metabolites to verapamil or the ratio of the combined o-demethylated to the N-dealkylated metabolites.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994898      PMCID: PMC1463828          DOI: 10.1111/j.1365-2125.1985.tb02678.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Clinical pharmacokinetics of calcium ion antagonists.

Authors:  M Eichelbaum
Journal:  Clin Invest Med       Date:  1980       Impact factor: 0.825

2.  Prediction of steady-state verapamil plasma concentrations in children and adults.

Authors:  J G Wagner; A P Rocchini; J Vasiliades
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

3.  Prolongation of verapamil elimination kinetics during chronic oral administration.

Authors:  J B Schwartz; D L Keefe; E Kirsten; R E Kates; D C Harrison
Journal:  Am Heart J       Date:  1982-08       Impact factor: 4.749

4.  Simultaneous determination of verapamil and its seven metabolites by high-performance liquid chromatography.

Authors:  M Kuwada; T Tateyama; J Tsutsumi
Journal:  J Chromatogr       Date:  1981-03-13

5.  Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.

Authors:  M Eichelbaum; P Birkel; E Grube; U Gütgemann; A Somogyi
Journal:  Klin Wochenschr       Date:  1980-09-15

6.  Differences between the plasma indocyanine green disappearance rates of normal men and women.

Authors:  J F Martin; M Mikulecky; T F Blaschike; J G Waggoner; J Vergalla; P D Berk
Journal:  Proc Soc Exp Biol Med       Date:  1975-12

7.  Cardiovascular action of verapamil in the dog with particular reference to myocardial contractility and atrioventricular conduction.

Authors:  J A Angus; D R Richmond; P Dhumma-Upakorn; L B Cobbin; A H Goodman
Journal:  Cardiovasc Res       Date:  1976-11       Impact factor: 10.787

8.  Reduced verapamil clearance during long-term oral administration.

Authors:  D G Shand; S C Hammill; L Aanonsen; E L Pritchett
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

9.  Verapamil kinetics in normal subjects and patients with coronary artery spasm.

Authors:  S B Freedman; D R Richmond; J J Ashley; D T Kelly
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

10.  Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies.

Authors:  D R Abernethy; E L Todd; J R Mitchell
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

View more
  10 in total

1.  Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

Authors:  D O Rumiantsev; V K Piotrovskii; V I Metelitsa; I D Slastnikova; E V Kokurina
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

Review 2.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

3.  Pharmacokinetics and pharmacodynamics of two formulations of verapamil.

Authors:  K K Hla; J A Henry; A N Latham
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

4.  Verapamil pharmacokinetics.

Authors:  P A Meredith; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

Review 5.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 6.  Pharmacokinetics of calcium antagonists under development.

Authors:  D R Abernethy; J B Schwartz
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

7.  Pharmacokinetic characterization of the antiarrhythmic drug diprafenone in man.

Authors:  D Trenk; F Wagner; W Sachs; E Jähnchen
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  The effect of oral verapamil therapy on antipyrine clearance.

Authors:  D O Rumiantsev; V K Piotrovskii; O S Riabokon; I D Slastnikova; E V Kokurina; V I Metelitsa
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Comparative single dose and steady-state pharmacokinetics of bevantolol in young and elderly subjects.

Authors:  A Selen; A W Kinkel; A C Darke; D S Greene; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.